Ulrich Keller

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 599 citations · Full text

Medicine, Immunology, Oncology +12

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

Jan R. Dörr, Yong Yu, Maja Milanovic et al. · Nature · 2013 · 539 citations

Medicine, Cancer Biology, Oncology +16

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

Caroline Voskens, Simone M. Goldinger, Carmen Loquai et al. · PLoS ONE · 2013 · 470 citations · Full text

Medicine, Oncology, Pharmacology +16

Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells

Katharina Timper, Dalma Seboek, Michael Eberhardt et al. · Biochemical and Biophysical Research Communications · 2006 · 449 citations

Life Sciences, Cell Biology, Endocrinology +14